Capricor Therapeutics to Hold Fourth Quarter 2014 Business Update Conference Call on March 18, 2015 at 4:30 p.m. EDT

LOS ANGELES, March 12, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that company management will hold a conference call to discuss fourth quarter and full year 2014 business highlights at 4:30 p.m. EDT, March 18, 2015.

Access to the live webcast and teleconference is provided below:

Additionally, conference call details and a link to the replay of the webcast to be archived for 90 days will be available at

About Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information visit

CONTACT: Corporate Contact Capricor Therapeutics, Inc. AJ Bergmann, Vice President of Finance +1-310-358-3200 Media Relations Russo Partners Christopher Hippolyte +1-646-942-5634 Tony Russo, Ph.D. +1-212-845-4251 Investor Relations: Russo Partners Robert Flamm, Ph.D. +1-212-845-4226

Source:Capricor Therapeutics